Neuren Pharmaceuticals Ltd

Chart & Performance

D1W1MN

P/E

11.01

P/S

7.33

EPS

1.12

Div Yield, %

—

Shrs. gr., 5y

5.48%

Rev. gr., 5y

236.40%

Revenues

213m

-8.06%

Net income

142m

-9.57%

CFO

-11m

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Neuren Pharmaceuticals Limited, an Australian biopharmaceutical firm, is dedicated to developing innovative treatments for neurological conditions. Its leading drug candidate, trofinetide, is currently in advanced (Phase III) clinical trials for Rett syndrome, following its successful completion of Phase II trials for Fragile X syndrome. The company is also progressing with NNZ-2591, which has finished its initial Phase I clinical studies for several disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. Beyond its therapeutic pipeline, Neuren Pharmaceuticals provides development services and holds loan-funded shareholdings. The company was founded in 2001 and operates from Camberwell, Australia.

URL

https://www.neurenpharma.com/

IPO date

Feb 03, 2005

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT